NUTROPIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NUTROPIN (NUTROPIN).

How it works

Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased IGF-1 production and subsequent anabolic, lipolytic, and anti-insulin effects.

What the body does with it

Metabolism	Metabolized in liver and kidneys via proteolysis; not significantly metabolized by CYP450 enzymes.
Excretion	Primarily renal; >99% of absorbed dose eliminated via glomerular filtration and tubular reabsorption, with minimal biliary excretion (<1%).
Half-life	Terminal elimination half-life of 3.9–4.1 hours following subcutaneous administration; intravenous half-life approximately 20–30 minutes due to rapid distribution.
Protein binding	~40% bound to growth hormone-binding protein (GHBP) in plasma.
Volume of Distribution	0.7–1.2 L/kg, reflecting distribution primarily into extracellular fluid, with limited tissue penetration.
Bioavailability	Subcutaneous: ~80%; intramuscular: ~70–75%; intravenous: 100%.
Onset of Action	Subcutaneous: 2–4 hours for increased serum IGF-1 levels; intramuscular: 3–6 hours; intravenous: immediate but short-lived (minutes).
Duration of Action	Subcutaneous: 12–24 hours as per once-daily dosing; IGF-1 levels peak at 12–18 hours post-dose. Clinical growth effects require weeks to months.

Classification & Brands

Dosing & administration

0.006 mg/kg subcutaneously once daily (maximum 0.025 mg/kg/day). May also be administered intramuscularly at 0.1-0.3 mg/kg per week divided into 3-7 doses.

Dosage form	Injectable
Renal impairment	No specific GFR-based dose adjustment recommended; use with caution in patients with moderate to severe renal impairment due to increased risk of fluid retention.
Liver impairment	No specific Child-Pugh based dose adjustments; monitor for edema and other adverse effects in patients with hepatic impairment.
Pediatric use	Growth hormone deficiency: 0.16-0.24 mg/kg subcutaneously per week divided into daily doses (0.023-0.034 mg/kg/day). Turner syndrome: 0.33 mg/kg subcutaneously per week divided into daily doses. Idiopathic short stature: 0.37-0.47 mg/kg per week. Chronic renal insufficiency: 0.35 mg/kg per week.
Geriatric use	Dosing should be individualized; lower starting doses recommended due to increased risk of adverse effects (e.g., edema, joint pain). Monitor closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NUTROPIN (NUTROPIN).

Breastfeeding	Excreted into human milk in trace amounts; M/P ratio not established. Low oral bioavailability limits infant exposure. Compatible with breastfeeding with monitoring.
Teratogenic Risk	No human data on fetal risk in first trimester. Animal studies show no teratogenicity at supratherapeutic doses. Somatropin does not cross placenta significantly. Considered low risk in all trimesters; use only if clearly needed.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Increased risk of mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure. Not approved for these conditions.

Side Effect Profile

Serious Effects

Absolute Contraindications

Acute critical illness (complications post-surgery or trauma), active malignancy, diabetic retinopathy, hypersensitivity to somatropin or excipients, children with closed epiphyses (for growth promotion).

Clinical Precautions

Precautions

Increased risk of malignancy, benign intracranial hypertension (pseudotumor cerebri), slipped capital femoral epiphysis, pancreatitis, fluid retention, glucose intolerance/diabetes mellitus, progression of scoliosis, and hypersensitivity reactions.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

NUTROPIN

Clinical safety rating: caution

Comprehensive clinical and safety monograph for NUTROPIN (NUTROPIN).

How it works

What the body does with it

Metabolism	Metabolized in liver and kidneys via proteolysis; not significantly metabolized by CYP450 enzymes.
Excretion	Primarily renal; >99% of absorbed dose eliminated via glomerular filtration and tubular reabsorption, with minimal biliary excretion (<1%).
Half-life	Terminal elimination half-life of 3.9–4.1 hours following subcutaneous administration; intravenous half-life approximately 20–30 minutes due to rapid distribution.
Protein binding	~40% bound to growth hormone-binding protein (GHBP) in plasma.
Volume of Distribution	0.7–1.2 L/kg, reflecting distribution primarily into extracellular fluid, with limited tissue penetration.
Bioavailability	Subcutaneous: ~80%; intramuscular: ~70–75%; intravenous: 100%.
Onset of Action	Subcutaneous: 2–4 hours for increased serum IGF-1 levels; intramuscular: 3–6 hours; intravenous: immediate but short-lived (minutes).
Duration of Action	Subcutaneous: 12–24 hours as per once-daily dosing; IGF-1 levels peak at 12–18 hours post-dose. Clinical growth effects require weeks to months.

Classification & Brands

Dosing & administration

0.006 mg/kg subcutaneously once daily (maximum 0.025 mg/kg/day). May also be administered intramuscularly at 0.1-0.3 mg/kg per week divided into 3-7 doses.

Dosage form	Injectable
Renal impairment	No specific GFR-based dose adjustment recommended; use with caution in patients with moderate to severe renal impairment due to increased risk of fluid retention.
Liver impairment	No specific Child-Pugh based dose adjustments; monitor for edema and other adverse effects in patients with hepatic impairment.
Pediatric use	Growth hormone deficiency: 0.16-0.24 mg/kg subcutaneously per week divided into daily doses (0.023-0.034 mg/kg/day). Turner syndrome: 0.33 mg/kg subcutaneously per week divided into daily doses. Idiopathic short stature: 0.37-0.47 mg/kg per week. Chronic renal insufficiency: 0.35 mg/kg per week.
Geriatric use	Dosing should be individualized; lower starting doses recommended due to increased risk of adverse effects (e.g., edema, joint pain). Monitor closely.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for NUTROPIN (NUTROPIN).

Breastfeeding	Excreted into human milk in trace amounts; M/P ratio not established. Low oral bioavailability limits infant exposure. Compatible with breastfeeding with monitoring.
Teratogenic Risk	No human data on fetal risk in first trimester. Animal studies show no teratogenicity at supratherapeutic doses. Somatropin does not cross placenta significantly. Considered low risk in all trimesters; use only if clearly needed.
Fetal Monitoring